Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study
OBJECTIVE: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy. SUBJECTS AND METHODS: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 ± 3.4) with oral sodium diclofenac, 50 mg every 12 hours. RESULTS: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment. CONCLUSIONS: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedade Brasileira de Endocrinologia e Metabologia
2011
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000900004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
oai:scielo:S0004-27302011000900004 |
|---|---|
| record_format |
ojs |
| spelling |
oai:scielo:S0004-273020110009000042012-01-05Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot studyBloise,WalterMimura,Lidia YuriMoura,JaneteNicolau,Wilian Moderate Graves' ophtalmopathy treatment sodium diclofenac PPAR-gamma cyclooxigenase-2 OBJECTIVE: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy. SUBJECTS AND METHODS: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 ± 3.4) with oral sodium diclofenac, 50 mg every 12 hours. RESULTS: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment. CONCLUSIONS: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArquivos Brasileiros de Endocrinologia & Metabologia v.55 n.9 20112011-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000900004en10.1590/S0004-27302011000900004 |
| institution |
SCIELO |
| collection |
OJS |
| country |
Brasil |
| countrycode |
BR |
| component |
Revista |
| access |
En linea |
| databasecode |
rev-scielo-br |
| tag |
revista |
| region |
America del Sur |
| libraryname |
SciELO |
| language |
English |
| format |
Digital |
| author |
Bloise,Walter Mimura,Lidia Yuri Moura,Janete Nicolau,Wilian |
| spellingShingle |
Bloise,Walter Mimura,Lidia Yuri Moura,Janete Nicolau,Wilian Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| author_facet |
Bloise,Walter Mimura,Lidia Yuri Moura,Janete Nicolau,Wilian |
| author_sort |
Bloise,Walter |
| title |
Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| title_short |
Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| title_full |
Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| title_fullStr |
Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| title_full_unstemmed |
Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study |
| title_sort |
treatment of mild to moderate graves' ophthalmopathy with sodium diclofenac: a pilot study |
| description |
OBJECTIVE: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy. SUBJECTS AND METHODS: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 ± 3.4) with oral sodium diclofenac, 50 mg every 12 hours. RESULTS: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment. CONCLUSIONS: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study. |
| publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
| publishDate |
2011 |
| url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000900004 |
| work_keys_str_mv |
AT bloisewalter treatmentofmildtomoderategravesophthalmopathywithsodiumdiclofenacapilotstudy AT mimuralidiayuri treatmentofmildtomoderategravesophthalmopathywithsodiumdiclofenacapilotstudy AT mourajanete treatmentofmildtomoderategravesophthalmopathywithsodiumdiclofenacapilotstudy AT nicolauwilian treatmentofmildtomoderategravesophthalmopathywithsodiumdiclofenacapilotstudy |
| _version_ |
1756372729635799040 |